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Background: Convalescent plasma and fractionated immunoglobulins have been suggested as prophylactic or
therapeutic interventions during an influenza pandemic.
Findings: Intravenous immunoglobulin (IVIG) preparations manufactured from human plasma collected before the
2009 H1N1 influenza pandemic, and post-pandemic hyperimmune (H)-IVIG preparations were characterized with
respect to hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase-inhibiting (NAi) antibody
titers against pandemic H1N1 (pH1N1) and seasonal H1N1 (sH1N1) viruses. The protective efficacy of the IVIG and
H-IVIG preparations was evaluated in a SCID mouse challenge model.
Substantial levels of HI, MN and NAi antibodies against pH1N1 (GMTs 1:45, 1:204 and 1: 727, respectively) and
sH1N1 (GMTs 1:688, 1:4,946 and 1:312, respectively) were present in pre-pandemic IVIG preparations. In post-pandemic
H-IVIG preparations, HI, MN and NAi antibody GMTs against pH1N1 were 1:1,280, 1:11,404 and 1:2,488 (28-, 56- and
3.4-fold enriched), respectively, compared to pre-pandemic IVIG preparations (p < 0.001). Post-pandemic H-IVIG (HI titer
1:1,280) provided complete protection from lethality of SCID mice against pH1N1 challenge (100%
of mice survived for 29 days post-challenge). Pre-pandemic IVIG (HI titer 1:70) did not provide significant protection
against pH1N1 challenge (50% of mice survived 29 days post-challenge compared to 40% survival in the buffer
control group). There was a highly significant correlation between circulating in vivo HI and MN antibody titers and
survival (p < 0001).
Conclusion: The substantial enrichment of HA- and NA-specific antibodies in H-IVIG and the efficacious protection of
SCID mice against challenge with pH1N1 suggests H-IVIG as a promising intervention against pandemic influenza for
immunocompromised patients and other risk groups.
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Infectious diseases were commonly managed by passive
transfer of human or animal sera prior to the develop-
ment of effective vaccines and antimicrobials, and pas-
sive transfer of convalescent sera is currently still used
to prevent and treat some viral and bacterial infections
[1,2]. The use of convalescent plasma and fractionated
immunoglobulins [3,4], and, more recently, monoclonal
antibodies [5-8], has been suggested as a complementary
strategy to prevent or treat virus infection during an in-
fluenza pandemic. Treatment of severe pH1N1 infection
with convalescent plasma or H-IVIG was associated with
lower viral load and reduced mortality [9,10].
As previously reported [11], we investigated the feasibility
of manufacturing H-IVIG as a response to the emergence
of the 2009 H1N1 pandemic (pH1N1) virus. H-IVIG prepa-
rations were shown to have significantly elevated levels of
pH1N1 hemagglutinating (HI) and neutralizing antibodies,
as assessed by microneutralization (MN) assay, compared
to standard IVIG preparations collected from donors either
during or before the H1N1 pandemic [11].
In the present study, we further characterized post-
pandemic H-IVIG preparations with respect to HI and
MN antibodies against both pH1N1 and a seasonal
H1N1 (sH1N1) virus (A/New Caledonia/20/1999, which
circulated in the Northern hemisphere and was a recom-
mended component of the trivalent seasonal vaccine from
2000–01 to 2006–07). We also assessed the level of pre-
existing cross-reactive pH1N1 immunity in the donor
population by determining the HI and MN titers against
pH1N1 and sH1N1 in pre-pandemic IVIG preparations.
In addition, we investigated the extent to which antibodies
capable of inhibiting the enzymatic activity of the sH1N1
and pH1N1 neuraminidase (NA) antigens were enriched
in the post-pandemic compared to pre-pandemic prepara-
tions. We also investigated the ability of pre-pandemic
IVIG and post-pandemic H-IVIG to protect highly sus-
ceptible immunodeficient SCID mice against challenge
with wild-type pH1N1 virus.
Methods
IVIG and H-IVIG
A total of 13 IVIG preparations (Gammagard Liquid/
KIOVIG, Baxter Healthcare, Westlake Village, CA) man-
ufactured from human plasma collected before the 2009
H1N1 influenza pandemic (manufactured January to
November 2009, plasma collected >6 months prior to
these dates), and two lots of post-pandemic H-IVIG
preparations (manufactured July 2010) [11] were charac-
terized in the present study. For IVIG production, col-
lected plasma was pooled into two 7500-L batches, and
the Cohn ethanol fractionation and downstream pro-
cesses for the two H-IVIG lots were performed in full
accordance with the licensed process for GammagardLiquid/KIOVIG, a triple virus-reduced 10% IVIG prepar-
ation [12,13].
Laboratory Assays
Pre-pandemic IVIG and H-IVIG preparations were char-
acterized with respect to HI and MN titers against
pH1N1 (A/California/07/2009 reassortant NYMC X-
179A), and sH1N1 (A/New Caledonia/20/1999), as pre-
viously described [11].
Antibodies capable of inhibiting the enzymatic activity
of NA (NAi antibodies) in the IVIG and H-IVIG prepa-
rations were detected using a highly sensitive enzyme-
linked lectin assay (ELLA), as previously described [14].
N1 antigens were obtained by splitting wild-type A/Cali-
fornia/07/2009 (CDC, Atlanta, GA) and A/New Caledo-
nia/20/1999 virus preparations by overnight incubation
with 0.5% Triton X-100 at 4°C, followed by detergent re-
moval using 20% Bio-Beads (Biorad).
Mouse passive transfer studies
6–8 week old SCID mice (strain CB17/Icr-Prkdcscid/
IcrCrl; Charles River Laboratories, Germany) were intra-
nasally infected with 30 μl containing 6×104 tissue cul-
ture infectious dose 50% (TCID50) of H1N1 strain A/
California/07/2009 (9.5-fold 50% lethal (LD50) dose [15])
and monitored 29 days. For passive protection studies,
mice were intraperitoneally injected three days prior to
challenge with 200 μl of H-IVIG, IVIG or PBS control.
Two independent experiments with two different lots of
H-IVIG (8–10 mice per group), and two independent
experiments with a pool of 5 lots of IVIG or PBS control
(10 mice per group) were done. For calculation of dose-
dependency, 200 μl of undiluted and 2-fold serial dilu-
tions of H-IVIG, undiluted IVIG or phosphate-buffered
saline (PBS) were used. Serum was obtained from ani-
mals before challenge, at Day 3, and at Day 32 to deter-
mine circulating in vivo antibody titers.
Statistical analysis
Statistical differences between IVIG and H-IVIG anti-
body titers were calculated from combined data by un-
paired Student t-test analysis. Differences in survival
were analyzed with a Log-rank (Mantel-Cox) test. The
significance of the correlation of in vitro and in vivo HI
and MN titers, as determined on Day 3 and Day 32, as
well as correlation of Day 3 antibody titers with survival
was evaluated using a nonparametric Spearman correl-
ation analysis (GraphPad Prism v.5.01 software).
Results and Discussion
To investigate the titers of antibodies against sH1N1 and
pH1N1 in pre-pandemic (n = 13) and post-pandemic
IVIG (n = 2) preparations, sera were analyzed by HI, MN
and NAi assays. Figure 1 shows HI, MN and NAi titers
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and post-pandemic H-IVIG preparations (hatched bars).
Pre-pandemic IVIG preparations had substantial HI, MN
and NAi titers against pH1N1 (grey bars) (geometric mean
titer [GMT] 1:45, 1:204 and 1:727, respectively), as well as
against sH1N1 (white bars) (GMT 1:688, 1:4,946, and 1:312
respectively). As expected, significantly higher HI, MN and
NAi antibody titers against pH1N1 were present in the
post-pandemic H-IVIG preparations compared to titers in
the pre-pandemic IVIG preparations (P < 0.0001 for all
serological assays). GMTs of 1:2,560 (HI), 1:11,404 (MN)
and 1: 2,488 (NAi) were determined for the post-pandemic
H-IVIG preparations, an increase of 28- 56- and 3.4-fold,
respectively, compared to pre-pandemic IVIG preparations.
In addition, higher titers of HI (1:2,560), MN (1:16,127) and
NAi (1:717) antibodies against sH1N1 were also present in
the post-pandemic H-IVIG preparations.
The finding that substantial levels of HI and MN anti-
bodies against pH1N1 were also present in the pre-
pandemic IVIG preparations is in agreement with other
vaccine and seroepidemiological studies which reported
high rates of seroprotective pre-exposure pH1N1 HI
and neutralizing antibody titers, likely as a result of
cross-reactive antibodies induced by repeated exposure
to seasonal H1N1 viruses [16]. The relatively low in-
crease in pH1N1-specific NA antibody titers in H-IVIG
likely reflects the high level of antigenic similarity be-
tween seasonal and pandemic H1N1 NA proteins [17].
To analyze the protective potential of pre-pandemic
IVIG and post-pandemic H-IVIG preparations, passive
transfer experiments were done in SCID mice. Adminis-
tration of post-pandemic H-IVIG, prior to challenge withFigure 1 Serological characterization of pre-pandemic IVIG (open bar
the seasonal H1N1 strain A/New Caledonia/20/1999 (sH1N1) (white bars) an
determined by hemagglutination inhibition (HI), microneutralization (MN) a
respectively. Results are given as geometric mean titer (GMT) ± 95% confid
Student t-test analysis (GraphPad Prism software). *** P < 0.0001. GMTs werwild-type pH1N1, provided complete protection (100%
survival) of SCID mice during the 29 days monitoring
period, whereas only 50% of animals receiving pre-
pandemic IVIG and 40% of animals receiving buffer sur-
vived (Figure 2). Increased survival rates (compared to
animals receiving pre-pandemic IVIG) afforded by post-
pandemic were highly statistically significant (Mantel-Cox
Log-rank P < 0.0001) but not for pre-pandemic IVIG com-
pared to buffer control (P = 0.15). The relatively long
survival time of the mice receiving buffer only is a result of
the relatively low pathogenicity of the pH1N1 virus in mice
[18,19]. Due to constraints of the challenge volume used, it
was however not possible to increase the challenge dose.
To investigate the extent to which protection against
pH1N1 challenge by H-IVIG administration is dose-
dependent, mice were administered with serial 2-fold
dilutions of H-IVIG prior to challenge with pH1N1.
Circulating in vivo HI and MN antibody titers were mea-
sured in sera taken from animals immediately prior to
challenge and at the end of the experiment i.e. 29 days after
virus challenge. Table 1 shows the HI and MN titers of H-
IVIG preparations administered to mice, the circulating
antibody titers measured at the time of challenge and
29 days after challenge, and the associated survival rates of
mice challenged with pH1N1 virus. Protection was
dose-dependent, and there was a highly significant cor-
relation (nonparametric Spearman correlation r = 0.9,
P <0.0001) between circulating in vivo HI and MN
antibody titers measured on the day of virus challenge
and survival.
Although these data demonstrate the potential of H-
IVIG as a potential prophylactic intervention in thes) and post-pandemic H-IVIG (hatched bars). Antibody titers against
d pandemic A/California/07/2009 (pH1N1) (grey bars) were
nd enzyme-linked lectin assay (ELLA, reported as NA inhibition [NAi]),
ence interval (CI). Statistical differences were calculated by unpaired
e calculated by testing 13 individual lots of IVIG and 2 lots of H-IVIG.
Figure 2 Protective efficacy of pre-pandemic IVIG and post-pandemic H-IVIG. To evaluate passive protection efficacy, SCID mice were
intraperitoneally administered with 200 μl of pH1N1 hyperimmune IVIG (two lots, HI titer 1:1,280) or pre-pandemic IVIG (pool of five lots, HI titer
1:70) 3 days prior to challenge with 6×104 TCID50 of wild-type pH1N1 by intranasal instillation. The control group received 200 μl of PBS and
survival was monitored for 29 days. Statistical differences between the IVIG group and the PBS control group, and between the IVIG group and
the H-IVIG group, were calculated with a Log-rank (Mantel-Cox) test using the GraphPad Prism software. Abbreviations: d, days; n.s., not significant;
IVIG, pre-pandemic intravenous immunoglobulin; H-IVIG, hyperimmune intravenous immunoglobulin.
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tions to our study. In addition to showing the protective
effect of H-IVIG with respect to survival of challenged
animals, it would have been interesting to investigate the
ability of H-IVIG to ameliorate disease symptoms (e.g.
by prevention of weight loss) and to reduce viral load
and cytokine levels in challenged animals. It would also
have been interesting to determine whether post-pandemic
H-IVIG also protects against influenza viruses of other sub-
types. Several studies have reported that infection or vac-
cination with pH1N1 boosted broadly neutralizing HA




In vitroa In vivo
Day 3b Day 32c
H-IVIG (undiluted) 1280 163 33
H-IVIG (1:2) 640 143 26
H-IVIG (1:4) 320 63 14
H-IVIG (1:8) 160 35 8
H-IVIG (1:16) 80 21 6
IVIG (undiluted) 70 6 7
Buffer control n.a. 5 5
ain vitro titer of neat samples determined prior to i.p. injection; titers of diluted H-IV
bmouse serum titers 3 days after passive transfer; i.e. at the time of challenge.
cmouse serum titers 32 days after passive transfer; i.e. 29 days after challenge.
HI, hemagglutination inhibition; MN, microneutralization; GMT, geometric mean tite
Note: IVIG was a pooled preparation from 5 different IVIG lots; 2 different lots of H-
independent experiments.An additional limitation is that we did not investigate
the potential therapeutic efficacy of H-IVIG. Several re-
cent studies have demonstrated that post-infection ad-
ministration of influenza-specific monoclonal antibodies
can effectively treat mice or ferrets which were pre-
viously subjected to virus challenge [5-8]. Treatment of
humans with severe pH1N1 infection with convalescent
plasma or H-IVIG was also associated with lower viral
load and reduced mortality [9,10]. However, prophylactic
passive administration of H-IVIG could be administered
to acutely immunocompromised individuals who are
at high-risk of serious complications resulting fromMN GMT % survival
In vitroa In vivo
Day 3b Day 32c
3420 349 34 100
1710 190 15 95
855 95 11 90
428 48 6 76
214 24 5 63
60 5 5 50
n.a. 5 5 40
IG are calculated accordingly.
r; n.a., not applicable.
IVIG were used separately. Data shown are combined data from 2
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fective response to vaccination, such as HIV patients,
transplant recipients and cancer patients. In the event
of a pandemic caused by a highly pathogenic influenza virus,
passive immunization might also be considered for first-
line health care workers and for direct contacts of infected
individuals.
Conclusion
Taken together, the data in this study demonstrating sub-
stantial enrichment of HA- and NA-specific antibodies in
H-IVIG and the efficacious protection of SCID mice
against challenge with pH1N1 indicate that H-IVIG could
be used as a prophylactic intervention against pandemic
influenza for immunocompromised patients and other
risk groups.
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